Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Left ventricular pacing proves equal to biventricular pacing

This article was originally published in Clinica

Executive Summary

In a study that may have important cost and safety implications for cardiac resynchronisation therapy for heart failure (HF), researchers found that pacing just the left ventricle, as opposed to the traditional practice of pacing both ventricles, may be sufficient for clinical benefit. Since pacing only the left ventricle reduces the number of leads a doctor must place in the heart when implanting a cardiac resynchronisation device, the approach promises to lead to improvements from technical, economical and safety points of view, a UK team reported.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT063673

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel